PPARG and metabolic dysfunction-associated steatotic liver disease: Simultaneously, PPAR‐γ activation enhances insulin sensitivity by upregulating insulin‐responsive genes, improving glycemic control, and reducing insulin resistance, which is central to MASLD pathology.